Valley National Advisers Inc. Reduces Stock Position in Sanofi (NASDAQ:SNY)

Valley National Advisers Inc. trimmed its holdings in Sanofi (NASDAQ:SNY) by 30.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,842 shares of the company’s stock after selling 3,036 shares during the period. Valley National Advisers Inc.’s holdings in Sanofi were worth $329,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in Sanofi by 0.4% in the second quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock valued at $15,466,000 after buying an additional 1,238 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Sanofi in the 2nd quarter worth approximately $344,000. The Manufacturers Life Insurance Company increased its holdings in shares of Sanofi by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company’s stock valued at $1,530,000 after acquiring an additional 6,756 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Sanofi by 27.2% during the 2nd quarter. NewEdge Advisors LLC now owns 29,587 shares of the company’s stock valued at $1,436,000 after acquiring an additional 6,330 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Sanofi by 5.5% during the second quarter. Cetera Investment Advisers now owns 188,159 shares of the company’s stock worth $9,130,000 after purchasing an additional 9,810 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY opened at $54.34 on Monday. The firm has a fifty day moving average of $49.24 and a 200-day moving average of $52.30. The company has a market cap of $137.91 billion, a price-to-earnings ratio of 21.82, a price-to-earnings-growth ratio of 1.26 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. As a group, equities analysts anticipate that Sanofi will post 4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.